Eduarda P. Martins

  • Neuro-oncology
  • Glioblastoma
  • Cancer
  • Biomarkers
  • Oncogenes
  • Tumor aggressiveness
  • CDH3
  • P-Cadherin
  • Patient-derived cultures

Eduarda P. Martins (EM) is a PhD student in Applied Health Sciences in collaboration between the ICVS, School of Medicine and Stemmatters, Biotecnologia e Medicina Regenerativa S.A. EM graduated in Applied Biology in 2016 (School of Sciences, UMinho). In 2018, she completed her Master’s degree in Health Sciences (School of Medicine, UMinho) supervised by Dr. Bruno M. Costa. During her post-graduation studies, EM received training in Laboratory Animal Science (being accredited by the national agency Direção Geral de Alimentação e Veterinária to work with animals for scientific purposes) and to be a trainer of the Laboratory Animal Sciences course.
Her main interests are focused on the study of brain tumors, namely glioblastoma, trying to identify prognostic biomarkers and mechanisms of aggressiveness. EM co-authored 8 publications in peer-reviewed journals (including 1 in Translational Research; 1 in Theranostics; 2 in Molecular Oncology; 2 in Cancers; 1 in Frontiers in Oncology; and 1 in International Journal of Pharmaceutics), including one as first author. Publications totalize an impact factor of 57.7 (average of 7.2).
EM also attended to several scientific meetings, contributing with 18 posters (11 as first author) and 10 oral presentations (6 as first author). These communications were awarded with 4 communication prizes, including the European Association for Cancer Research Poster Prize in the 3rd Portuguese Association for Cancer Research International Congress as first author. EM was also awarded with a travel grant to participate in the 11th Brain Tumor Meeting in Berlin.

Scientific Highlights

1. Martins EP, Gonçalves CS, Pojo M, Carvalho R, Ribeiro AS, Miranda-Gonçalves V, Taipa R, Pardal F, Pinto AA, Custódia C, Faria CC, Baltazar F, Sousa N, Paredes J, Costa BM. Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma. Mol Oncol. 2022 Jul;16(14):2611-2631. doi: 10.1002/1878-0261.13162. Epub 2022 Jun 10. PMID: 34919784; PMCID: PMC9297769.
2. Lopes MB, Martins EP, Vinga S, Costa BM. The Role of Network Science in Glioblastoma. Cancers (Basel). 2021 Mar 2;13(5):1045. doi: 10.3390/cancers13051045. PMID: 33801334; PMCID: PMC7958335.
3. Gonçalves CS, Vieira de Castro J, Pojo M, Martins EP, Queirós S, Chautard E, Taipa R, Pires MM, Pinto AA, Pardal F, Custódia C, Faria CC, Clara C, Reis RM, Sousa N, Costa BM. WNT6 is a novel oncogenic prognostic biomarker in human glioblastoma. Theranostics. 2018 Sep 9;8(17):4805-4823. doi: 10.7150/thno.25025. PMID: 30279739; PMCID: PMC6160775.
4. Gonçalves CS, Xavier-Magalhães A, Martins EP, Pinto AA, Pires MM, Pinheiro C, Reis RM, Sousa N, Costa BM. A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis. Mol Oncol. 2020 Jun;14(6):1224-1241. doi: 10.1002/1878-0261.12633. Epub 2020 May 6. PMID: 31923345; PMCID: PMC7266278.
5. Vieira de Castro J, Gonçalves CS, Martins EP, Miranda-Lorenzo I, Cerqueira MT, Longatto-Filho A, Pinto AA, Reis RL, Sousa N, Heeschen C, Costa BM. Intracellular Autofluorescence as a New Biomarker for Cancer Stem Cells in Glioblastoma. Cancers (Basel). 2021 Feb 16;13(4):828. doi: 10.3390/cancers13040828. PMID: 33669350; PMCID: PMC7920313.
6. Lopes M, Vieira de Castro J, Pojo M, Gonçalves CS, Martins EP, Coimbra B, Sotiropoulos I, Sousa N, Rodrigues AJ, Costa BM. Chronic Stress Does Not Influence the Survival of Mouse Models of Glioblastoma. Front Oncol. 2022 Mar 25;12:856210. doi: 10.3389/fonc.2022.856210. PMID: 35402232; PMCID: PMC8990973.
7. Outeiro-Pinho G, Barros-Silva D, Moreira-Silva F, Lobo J, Carneiro I, Morais A, Martins EP, Gonçalves CS, Costa BM, Correia MP, Henrique R, Jerónimo C. Epigenetically-regulated miR-30a/c-5p directly target TWF1 and hamper ccRCC cell aggressiveness. Transl Res. 2022 Jun 11:S1931-5244(22)00141-4. doi: 10.1016/j.trsl.2022.06.009. Epub ahead of print. PMID: 35697274.
8. Oliveira C, Gonçalves CS, Martins EP, Neves NM, Reis RL, Costa BM, Silva TH, Martins A. Fucoidan/chitosan nanoparticles functionalized with anti-ErbB-2 target breast cancer cells and impair tumor growth in vivo. Int J Pharm. 2021 May 1;600:120548. doi: 10.1016/j.ijpharm.2021.120548. Epub 2021 Mar 29. PMID: 33794324.

9. Team member of FCT funded projects: “Exploiting the immune landscape of HOXA9/WNT6-driven glioblastoma: opportunities for novel precision therapies” (reference 2022.04859.PTDC); “Tracking brain tumors through their exosomes: a WNT6-driven approach” (reference 2022.05143.PTDC); “MONET: Muti-Omic NETworks in gliomas” (reference PTDC/CCI-BIO/4180/2020); .

10. European Association for Cancer Research Poster Prize in the 3rd Portuguese Association for Cancer Research International Congress (Lisbon, May 2018).


Multi-omic networks in gliomas (MONET)

Gliomas, the most common primary brain tumors, arise from the glial cells and typically exhibit bad prognosis. In particular, glioblastoma (GBM), the most common and aggressive…

Read More